Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy of hyper-Lp(a).

K M Kostner1, G M Kostner

  • 1Research Wing Level 3, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. KKostner@soms.pa.uq.edu.au

Handbook of Experimental Pharmacology
|April 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Der Internist·2014
Same author

Fluorescence labeling and interaction of atherogenic lipoproteins with cultured cells.

Journal of fluorescence·2013
Same author

Transfer of pyrene-dietherphosphatidylcholine to serum lipoproteins.

Journal of fluorescence·2013
Same author

Expression of fat mobilizing genes in human epicardial adipose tissue.

Atherosclerosis·2011
Same author

Does lipoprotein(a) predict risk in type 2 diabetes?

European journal of clinical investigation·2006
Same author

Plasma delipidation process induces rapid regression of atherosclerosis and mobilisation of adipose tissue.

Journal of clinical apheresis·2005

Elevated Lipoprotein (a) [Lp(a)] is a significant cardiovascular risk. Current treatments are ineffective, necessitating novel therapies targeting Lp(a) metabolism for hyper-Lp(a) patients.

Area of Science:

  • Cardiovascular Biology
  • Lipid Metabolism
  • Pharmacology

Background:

  • Lipoprotein (a) [Lp(a)] is a highly atherogenic lipoprotein, comprising an LDL core and apolipoprotein (a) [apo(a)].
  • Lp(a) levels are predominantly genetically determined (>90%) and influenced by apo(a) biosynthesis.
  • Impaired catabolism, as seen in kidney disease, can elevate Lp(a) levels significantly.

Purpose of the Study:

  • To review the current understanding of Lp(a) metabolism and its clinical implications.
  • To highlight the lack of effective treatments for elevated Lp(a).
  • To explore potential therapeutic strategies for hyper-Lp(a).

Main Methods:

  • Literature review of Lp(a) structure, genetics, metabolism, and therapeutic interventions.
  • Analysis of factors influencing Lp(a) levels, including genetic, hormonal, and disease-related aspects.

Related Experiment Videos

  • Evaluation of the efficacy and limitations of existing lipid-lowering drugs on Lp(a).

    • Main Results:

    • Lp(a) size polymorphism is linked to kringle-4 Type-II repeats in apo(a).
    • Plasma Lp(a) levels correlate with apo(a) biosynthesis, with limited influence from diet or lifestyle.
    • Anabolic steroids are the only agents found to significantly reduce Lp(a), but are unsuitable for therapeutic use.

    Conclusions:

    • There is a critical need for specific medications targeting Lp(a) biosynthesis, assembly, or catabolism.
    • Further research into anabolic steroid mechanisms could lead to safer, targeted Lp(a) therapies.
    • Development of novel drugs is essential for managing hyper-Lp(a) and reducing cardiovascular risk.